NovellusDx Registers Another Patent On FACT™

Jerusalem, Israel Last month NovellusDx was granted Israel Patent #239624 For METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER MUTATIONS for its Functional Annotation of Cancer Treatment technology. The patent, which will remain in force until 2034, adds to...

read more

NovellusDx presenting in CiMED

California, US. NovellusDx will be presenting on June 7 as part of the Israeli delegation organized by the California Israel Chamber of Commerce. CiMED connects Israeli MedTech companies to the Silicon Valley health and medical technology ecosystem, including...

read more

NovellusDx in MIXiii Biomed 2017

Tel Aviv, Israel. NovellusDx abstract, titled “NovellusDx Functional Oncology Diagnostics” has been  accepted for oral presentation by the scientific committee of the MIXiii Biomed 2017 to be held in Tel Aviv, Israel on May 23, 2017 at 12:25 PM in a company...

read more

NovellusDx Opens Its High-Throughput Commercial Clinical Lab

Jerusalem, Israel. NovellusDx Clinical Laboratory is up and running. NovellusDx clinical lab is both CMS and NY state CLIA certified and can serve patients from the US and internationally. In November 2015, the lab received ISO 13485:2003 for the “development of...

read more